Legend Biotech (LEGN) CFO Carlos E. Santos Receives Award, Sells Shares

What Happened

• Carlos E. Santos, Chief Financial Officer of Legend Biotech Corp (LEGN), had an award/acquisition of 19,676 ordinary shares effective 2026-09-21 (reported as $0.00 cost, consistent with a stock award/vesting). On the same date he disposed of 5,430 ordinary shares in an open-market sale, generating approximately $49,630.
• The sale was a routine withholding sale to satisfy tax obligations related to the vesting of restricted share units (RSUs), not necessarily a discretionary cash-raising trade.

Key Details

• Transaction dates: 2026-09-21; Form 4 filed 2026-09-23 (filed two days after the transactions, within the SEC’s usual 2-business-day reporting window).
• Sale price: weighted average $9.14 per ordinary share; reported sale prices ranged from $8.905 to $9.325 (report notes full breakdown available on request).
• Award: 19,676 ordinary shares reported as acquired at $0.00 (indicative of RSU vesting or similar award).
• Reason for sale: footnote states shares were sold to satisfy withholding tax on RSU vesting.
• Shares owned after the transactions: not provided in the data you supplied.
• ADS note: the company’s ordinary shares may be represented by American Depositary Shares (ADSs); one ADS = two ordinary shares.

Context

• This combination of an award/vesting and a simultaneous sell-to-cover for taxes is common for executives receiving RSUs and is generally considered administrative (tax-related) rather than a directional bet on the stock.
• For investors, purchases by insiders can be more informative than routine sell-to-cover transactions; here, the acquisition reflects vesting of compensation rather than an out-of-pocket buy.